These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 20839895)

  • 21. The initial treatment of Parkinson's disease should begin with levodopa.
    Weiner WJ
    Mov Disord; 1999 Sep; 14(5):716-24. PubMed ID: 10495031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage.
    Parkinson Study Group
    Clin Neuropharmacol; 2007; 30(2):72-85. PubMed ID: 17414939
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacologically distinct pramipexole-mediated akinesia vs. risk-taking in a rat model of Parkinson's disease.
    Holtz NA; Tedford SE; Persons AL; Grasso SA; Napier TC
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Oct; 70():77-84. PubMed ID: 27216282
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Drugs and drug delivery in PD: optimizing control of symptoms with pramipexole prolonged-release.
    Rascol O
    Eur J Neurol; 2011 Mar; 18 Suppl 1():3-10. PubMed ID: 21255197
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Pramipexole in Parkinson disease. Results of a treatment observation].
    Reichmann H; Brecht HM; Kraus PH; Lemke MR
    Nervenarzt; 2002 Aug; 73(8):745-50. PubMed ID: 12242961
    [TBL] [Abstract][Full Text] [Related]  

  • 27. P2B001 (Extended Release Pramipexole and Rasagiline): A New Treatment Option in Development for Parkinson's Disease.
    Hauser RA; Giladi N; Poewe W; Brotchie J; Friedman H; Oren S; Litman P
    Adv Ther; 2022 May; 39(5):1881-1894. PubMed ID: 35267155
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of pramipexole extended-release in Parkinson's disease: a review based on meta-analysis of randomized controlled trials.
    Shen T; Ye R; Zhang B
    Eur J Neurol; 2017 Jun; 24(6):835-843. PubMed ID: 28480621
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of a once-daily extended-release formulation of pramipexole switched from an immediate-release formulation in patients with advanced Parkinson's disease: results from an open-label study.
    Takanashi M; Shimo Y; Hatano T; Oyama G; Hattori N
    Drug Res (Stuttg); 2013 Dec; 63(12):639-43. PubMed ID: 23884661
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dilemma in Parkinson's Treatment; Levodopa Monotherapy May be the Best Choice.
    Abbasi MH; Esmaeili S; Habibi SA; Shahidi GA
    J Clin Neurosci; 2020 Sep; 79():219-223. PubMed ID: 33070900
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial.
    Poewe WH; Rascol O; Quinn N; Tolosa E; Oertel WH; Martignoni E; Rupp M; Boroojerdi B;
    Lancet Neurol; 2007 Jun; 6(6):513-20. PubMed ID: 17509486
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pramipexole in the treatment of Parkinson's disease: new developments.
    Möller JC; Oertel WH
    Expert Rev Neurother; 2005 Sep; 5(5):581-6. PubMed ID: 16162081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial.
    Poewe W; Rascol O; Barone P; Hauser RA; Mizuno Y; Haaksma M; Salin L; Juhel N; Schapira AH;
    Neurology; 2011 Aug; 77(8):759-66. PubMed ID: 21832218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost effectiveness of rasagiline and pramipexole as treatment strategies in early Parkinson's disease in the UK setting: an economic Markov model evaluation.
    Haycox A; Armand C; Murteira S; Cochran J; François C
    Drugs Aging; 2009; 26(9):791-801. PubMed ID: 19728752
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease.
    Hauser RA; Schapira AH; Barone P; Mizuno Y; Rascol O; Busse M; Debieuvre C; Fraessdorf M; Poewe W;
    Eur J Neurol; 2014 May; 21(5):736-43. PubMed ID: 24834511
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pramipexole versus sertraline in the treatment of depression in Parkinson's disease: a national multicenter parallel-group randomized study.
    Barone P; Scarzella L; Marconi R; Antonini A; Morgante L; Bracco F; Zappia M; Musch B;
    J Neurol; 2006 May; 253(5):601-7. PubMed ID: 16607468
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic evaluation of pramipexole.
    Antonini A; Calandrella D
    Expert Opin Drug Metab Toxicol; 2011 Oct; 7(10):1307-14. PubMed ID: 21892895
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double blind, placebo controlled multicentre study.
    Pogarell O; Gasser T; van Hilten JJ; Spieker S; Pollentier S; Meier D; Oertel WH
    J Neurol Neurosurg Psychiatry; 2002 Jun; 72(6):713-20. PubMed ID: 12023411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ropinirole and pramipexole, the new agonists.
    Hobson DE; Pourcher E; Martin WR
    Can J Neurol Sci; 1999 Aug; 26 Suppl 2():S27-33. PubMed ID: 10451757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of pramipexole on depressive symptoms in Parkinson's disease.
    Yasui N; Sekiguchi K; Hamaguchi H; Kanda F
    Kobe J Med Sci; 2011 Feb; 56(5):E214-9. PubMed ID: 21937869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.